Webinar Event to Be Held
Tomorrow June 29th at 12pm Eastern / 9am Pacific Time
SAN DIEGO, CA -- June 28, 2021 -- InvestorsHub NewsWire -- Sigyn
Therapeutics, Inc. (OTCMarkets:
SIGY), a medical technology company focused on the treatment of
sepsis and other life-threatening inflammatory conditions
precipitated by Cytokine Storm Syndrome, announced today that its
Chairman and CEO, Jim Joyce will participate in a webinar entitled:
“The Evolution of Blood Purification Technologies to Treat Emerging
Pandemic Threats, Including COVID-19.” The event will be held
tomorrow at 12pm eastern.
Event registration can be accessed through the following
link: https://forcewealth.com/portfolio-items/sigyn-06-29/?portfolioCats=28
Prompted by 911 and the October 2001 Anthrax attacks, the
industry to support the development of drug and vaccine
countermeasures to treat emerging bioterror and pandemic threats
was established when President George W. Bush signed Project
BioShield into law. Mr. Joyce will review the congressional effort
that expanded Project BioShield to be inclusive of blood
purification devices and will additionally discuss how COVID-19 has
unveiled the ability of blood purification therapies to deliver
life-saving mechanisms that are beyond the reach of post-infection
drugs. Thus, establishing the potential for an important new
industry segment.
Beyond a review of Sigyn Therapy, technologies to be discussed
will include the Hemopurifier from Aethlon Medical, the CytoSorb
device from CytoSorbents Corporation, Torymyxin from Toray
Industries, the Oxiris Filter from Baxter and the Seraph 100
Microbind Affinity Blood Filter from Exthera Medical.
Note: In addition to co-founding Sigyn Therapeutics, Mr.
Joyce was the founder of Aethlon Medical and oversaw the
development of the Aethlon Hemopurifier.
About Sigyn Therapeutics
Sigyn Therapeutics™ is focused on significant unmet need in
global health; the treatment of life-threatening inflammatory
conditions that are precipitated by Cytokine Storm Syndrome. The
annual market opportunity exceeds $20 billion.
Sigyn Therapy™ is a multifunctional blood purification
technology designed to mitigate the Cytokine Storm that underlies
Sepsis (the #1 cause of in-hospital deaths) and other
high-mortality inflammatory disorders commonly induced by bacterial
and viral pathogens. To overcome the limitations of previous
therapies, Sigyn Therapy addresses the source of inflammation
(viral pathogens, bacterial toxins) in concert with the
broad-spectrum depletion of inflammatory cytokines from the
bloodstream. Additionally, the device establishes a
therapeutic strategy to target CytoVesicles that transport
inflammatory cargos throughout the circulatory system.
Sigyn Therapy incorporates a formulation of adsorbent components
that optimize the broad-spectrum elimination of therapeutic targets
from the bloodstream without the risk of direct blood-cell
interactions. To support widespread implementation, Sigyn Therapy
is a single-use disposable device designed for use on the
established infrastructure of hemodialysis and continuous renal
replacement therapy (CRRT) machines already located in hospitals
and clinics worldwide. The Company is also conducting studies to
evaluate the potential use of Sigyn Therapy to treat acute forms of
liver failure, including hepatic encephalopathy.
To learn more, visit www.SigynTherapeutics.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Sigyn
Therapeutics, Inc. (“Sigyn”) that involve substantial risks and
uncertainties. All statements contained in this press release are
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. The words “could,”
“will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,”
“potential,” or the negative of these terms or other similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements include, among
others, statements about Sigyn’s future financial performance, the
impact of management changes, any proposed organizational
restructuring, results of operations, capital resources to fund
operations; statements about Sigyn’s expectations regarding the
capitalization, resources and ownership structure of the combined
company; statements about the potential benefits of the
transaction; the expected completion and timing of the transaction
and other information relating to the transaction; and any other
statements other than statements of historical fact. Actual results
or events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements that Sigyn
makes due to a number of important factors, including (i) the risk
that the transaction may not be completed in a timely manner or at
all, which may adversely affect Sigyn’s business and the price of
the common stock of Sigyn, (ii) the failure to satisfy of the
conditions to the consummation of the transaction, (iii) the
occurrence of any event, change or other circumstance that could
give rise to the termination of the merger agreement, (iv) risks
related to the ability to realize the anticipated benefits of the
transaction, including the risk that the businesses will not be
integrated successfully, (v) the effect of the announcement or
pendency of the transaction on Sigyn’s business relationships,
operating results and business generally, (vi) risks that the
proposed transaction disrupts current plans and operations, (vii)
risks related to the combined entity’s ability to up-list to a
national securities exchange, (viii) risks related to the combined
entity’s access to existing capital and fundraising prospects to
fund its ongoing operations, (ix) risks related to diverting
management’s attention from Sigyn’s ongoing business operations,
(x) other business effects, including the effects of industry,
market, economic, political or regulatory conditions, future
exchange and interest rates, and changes in tax and other laws,
regulations, rates and policies, and (xi) risks related to an
inability to manufacture Sigyn Therapy, risks related to the
clinical advancement of Sigyn Therapy with regulatory agencies, and
no assurance that Sigyn Therapy will be proven to be a safe and
efficacious treatment for any condition. The forward-looking
statements in this press release represent Sigyn’s views as of the
date of this press release. Sigyn anticipates that subsequent
events and developments may cause its views to change. However,
while it may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. You should, therefore, not rely on these forward-looking
statements as representing Sigyn’s views as of any date subsequent
to the date of this press release.
Media Contacts:
Russo Partners, LLC
David Schull
(212) 845-4271
David.Schull@russopartnersllc.com
Nic Johnson
(212) 845-4242
Nic.Johnson@russopartnersllc.com
Corporate Contact:
Jim Joyce
Chairman, CEO
(619) 368-2000
jj@sigyntherapeutics.com
Sigyn Therapeutics (QB) (USOTC:SIGY)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Sigyn Therapeutics (QB) (USOTC:SIGY)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
